Pheochromocytomas are usually recognized by the effects of overproduction of catecholamines, but there are clinical features that cannot be ascribed to catecholamine excess that may be due to vasoactive peptides. We, therefore, measured blood levels of vasoactive intestinal peptides (VIP), substance P, somatostatin (SS), and motifin in 50 instances in 37 patients with pheochromocytomas---21 malignant, 10 benign intra-adrenal, and 6 ectopic (5 paracardial and 1 perirenal). Hormone levels were considered raised if the level was more than 3 S.D. above the mean value found in 52 healthy subjects. Of the 37 patients, 20 (54%) had an abnormality in 1 or more gut hormone levels. The most common abnormality was a raised SS in 9/37 (24%). In addition to these, however, 3 (8%) others had raised VIP, 5 (13.5%) raised motilin, and 3 (8%) raised substance P. Patients with benign adrenal adenomas had raised levels of SS and substance P. Ectopic pheochromocytomas produced only SS in addition to catecholamines, but malignant pheochromocytomas could secrete all 4 peptides, and more than 1 in the same patient. We conclude that pheochromocytomas may secrete multiple vasoactive peptides, and they are more likely to do so if malignant. Somatostatin is the most commonly secreted peptide and is found with benign adrenal and ectopic (paracardiac) tumors. If the level of more than 1 peptide is elevated, the likelihood of malignancy is significantly increased.
. The clinical manifestations of theseTffmors are protean and typically include hypertension (which may be severe, labile, paroxysmal, or may alternate with hypotension) and "spells" of episodic symptoms which tend to be stereotyped in each given patient and which may include various combinations of sweating, palpitations, pallor, anxiety, abdominal pain, chest pain, nausea, and tremor. These symptoms and signs may be ascribed to the increased levels of the catecholamines. The biochemical confirmation of the diagnosis lies in documenting this by assay of plasma catecholamine concentrations and/or urinary catecholamine excretion rates [4--6] .
Pheochromocytomas are tumors derived from the chromaffin neuroendocrine cells of the sympathoadrenal medullary system and can occur at any site from the base of the skull to the pelvic floor. The most common site (90%) is the adrenal medulla, the site of the majority of chromaffin tissues in the adult. Ten percent of lesions are extra-adrenal and most commonly occur in the para-aortic ganglia (including the organ of Zuckerkandl); other extraadrenal sites include the renal hilum; paravertebral autonomic, paracardiac, and cervical paraganglia, and the urinary bladder. Approximately 10% of pheochromocytomas are malignant and show either marked local invasive properties and/or metastasize, most commonly to the axial skeleton and less often to lymph nodes, liver, and lung.
The chromaffin cells form part of the APUD (amine precursor uptake and decarboxylation) system [7-I0] . This system is believed to be embryologically derived from primitive neuroectoderm and includes the central nervous system as well as many components of the endocrine system, including the sympathoadrenal medullary system, parathyroid glands, C cells of the thyroid gland, and possibly the endocrine pancreas and the enteric hormonal cell system.
The principal humoral factors secreted by the adrenomedullary sympathetic chromaffin system are the catecholamines including dopamine and norepinephrine. In the case of the adrenal medulla, an additional methyltransferase is present, which (in the presence of glucocorticoids from the adrenal cortex) converts norepinephrine to epinephrine. Although the biogenic amines are prominent in the secretory products of the chromaffin system, other factors are present. These include numerous peptides belonging to the group of so-called brain-gut peptides or neurohumoral factors [11] [12] [13] . Under this heading are included vasoactive intestinal peptides (VIP), substance P, somatostatin (SS), various opiate peptides, and motilin, which have been shown to occur in normal chromaffin tissues or tumors derived from such tissues [11] . The hypersecretion of these brain-gut neuropeptides may contribute to certain symptoms and signs that may occur with pheochromocytoma but in which hypercatecholaminemia cannot be clearly identified (e.g., flushing, bronchospasm, diarrhea, constipation) or may contribute in association with catecholamines to other symptoms (e.g., hyperglycemia, hypotension). This study undertook to measure a variety of brain-gut peptides in a group of patients with a variety of pheochromocytomas to determine the prevalence of hypersecretion.
Materials and Methods

Patient Population
A total of 37 patients with proven pheochromocytomas were studied. They were part of a large group referred for ~31I meta-iodobenzylguanidine (MIBG) scintigraphy to locate suspected pheochromocytomas or to evaluate the extent of known disease. The nature of the lesions present was as follows: 21 malignant, 10 benign intra-adrenal, and 6 extraadrenal primary tumors (5 paracardiac and 1 perirenal). The clinical and hormonal details of individua! patients are presented in Tables 1 and 2 . Histologic confirmation of the tumor was obtained in every patient, either by examination of tissue excised following operation performed at this institution or by review of tissue blocks or sections obtained following operation elsewhere. The light microscopic features of pheochromocytomas were present in all patients and immunohistochemistry was positive for chromogranin and neuron-specific enolase in all those patients in whom this was sought.
Laboratory Methods
131I-MIBG scintigraphy was performed as described previously [14] . The images were interpreted using previously described criteria [14] [15] [16] . The results of 13~I-scintigraphy were correlated with those of computed tomography (CT) scan, ultrasound, angiography, venous sampling, and surgical exploration (in various combinations).
Assays of catecholamines in plasma were carried out by the dual isotope radioenzymatic assay of Peuler and Johnson [17] . The least detection limit for epinephrine was 20 picograms (pg)/ml and for norepinephrine it was 40 pg/ml. The coefficient of interassay variability was +__ 5%. Blood samples were drawn in the fasted, resting, supine state through an indwelling needle left in situ for at least 30 minutes. Blood was placed in prechilled tubes on ice and the plasma was separated within 30 minutes and frozen at -70~ until assay. The urinary excretion rates of catecholamines and catecholamine metabolites were measured on 12-hr overnight (7 p.M.-7 A.~.) urine collection. Excretion rates were expressed in ixg/24 hr and are presented in Table 1 .
Blood samples for the measurement of peptide hormones were drawn in the fasted resting state into the following prechilled tubes, edetate (EDTA), EDTA with aprotinin (Trasylol FBA NJ 1,000 U/ml), heparinized, and plain tubes for serum. Samples were placed on ice separated within 30 minutes and frozen at -30~ until assay.
Plasma peptide hormone assays were carried out using previously described radioimmunoassays (somatostatin [18] ; motilin [19] ; VIP [20] and substance P [21] ). The intra-assay coefficient of variation of these assays was < 5% and all samples were run in the same assay for individual hormones. The crossreactions for SS28 in the SS14 assay was 66% and samples were not subjected to fractionation.
Statistical analysis of the significance of the relationship between hormone concentrations was carfled out by the method of least means square regression and differences between groups by categorical analysis. Significance was accepted at the 5% level.
Immunohistochemistry was carried out by the method of Sternberger et al. [22] and tissue and blood levels of chromogranin and neuron-specific enolase as described previously [23, 24] .
Results
The clinical features including the demographic, radiological, and scintigraphic data are presented in Table 1 . The plasma and urinary catecholamines and hormone profiles are presented in Table 2 .
Of the 37 patients, 21 were found to have malignant metastatic tumors, 10 had intra-adrenal tu- 82  683  19  330  23  47  95  7  94  9  7  702  74  218  21  26  461  387  690  746  31  221  454  1,429  941  121  81  64  99  15  6  453  158  3,968  145  20  563  34  355  6  31  307  13  1,332  103  21  69  0.3  3,826  10  5  36  2  2,186  36  3  31  4  1,500  108  2  299  7  567  43  21  2,746  14  124  5  150  2,496  142  1,669  24  75  98  7  163  51  7   97  10  5  300  101  10  5  449  72  10  5  281  71  10  5  159   27  10  54  49  10  8  188  1,184  10  20  232  112  10  341  139  52  10  55  232  93  10  5  119  44  10  18  245  99  10  5  101  8O  10  5  105  81  10  11  270  10  5  208   96  22  526  54  10  18  460  1,065  10  5  1,852  91  10  9  170   78  10  13  283  443  10  7  111  85  10  5  124  551  150  10  167  70  14  341  37  5  683  6  323  21  48  71  10  29  194 NE --norepinephrine; E = epinephrine; nmeta = normetanephrine; meta = metanephrine; VMA = vanillylmandelic acid; SRIF = somatostatin; VIP = vasoactive intestinal peptide. mors, either single or multiple, and 6 had ectopic tumors. Of the 6 ectopic tumors, 5 were paracardiac and 1 was perirenal. This unusual distribution of benign versus malignant pheochromocytomas is based on the fact that these patients were referred from outside centers for localization of the tumors by the MIBG method and thus constitute a unique group of patients. Abnormal elevation of 1 of the 4 hormones was found in 13 (62%) of 21 patients with malignancy, 5 (50%) of 10 of those with intra- found between any of the measurements of catecholamines and the degree or extent of elevation of the GEP hormones (Fig. 2) . adrenal tumors, and 2 (33%) of 6 of those with ectopic tumors. The most commonly raised hormone was somatostatin (24%), followed by motilin (13.5%), substance P (8%), and VIP (8%) (Fig. 1) . In 2 patients there was elevation of 2 hormones. One patient had high levels of motilin and SS and the other, substance P and SS. Only in 1 patient with a malignant tumor was there elevation of all 4 peptides and, furthermore, only in malignant tumor patients did the elevation of 2 peptides coexist. The overall prevalence of abnormal elevation of gastroenteropancreatic (GEP) hormones was 20 (54%) of 37 patients. Although in the ectopic tumors there was elevation only of SS, the difference between ectopic, intra-adrenal, and malignant tumors was not significant. There was no correlation Table 1 ) was a 56-year-old white male who presented to another hospital with pain and discomfort secondary to a right suprarenal tumor, the nature of which was not immediately apparent.
The lesion was hypervascular and parasitized the blood supply from the right renal artery. In addition, he had pain from pathologic fractures of the neck of the right humerus and the shaft of the left femur. A biopsy from the femoral lesion was interpreted as transitional carcinoma. He was also found to be diabetic and hypertensive. He had been treated with alpha-methyldopa, propranolol, hydralazine, and chlorpropamide. He was admitted for chemotherapy but developed an attack of acute pallor, marked diaphoresis, epigastric discomfort, and chest pain with diffuse wheezing. Hypertension was prominent. His subsequent course was marked by severe intractable dyspnea, wheezing, and hypertension. The bronchospasm was unresponsive to steroids, aminophylline, atropine, prostaglandin inhibitors, H1 and H2 antagonists, or beta adrenergic agonists. A persistently elevated pulmonary wedge pressure of 35 mm Hg was observed in the absence of left heart failure, fluid overload, or pulmonary emboli and required positive pressure ventilation.
Review of the histologic features with the use of special silver stains revealed the tumor to be of neuroendocrine origin. There was intense argyrophyUia with Grimelius silver stain. Immunohistochemical tests for insulin, glucagon, pancreatic polypeptide, and calcitonin were negative. Plasma catecholamines were markedly elevated (epinephrine 654 pg/ml, norepinephrine 1,477 pg/ml); 5- HIAA was normal and calcitonin was slightly raised (0.58 and 0.49 ng/ml).
At this point it was felt that the patient was suffering from bronchospastic and vasospastic effects of a neurohumoral factor secreted by the tumor. Somastostatin was markedly raised (551 pg/ml) as was substance P (150 pg/ml). 13q-MIBG scintigraphy revealed areas of uptake in the right suprarenal region with multiple bony and lung metastases (Fig. 3) . Pulmonary infiltrates were progressive and thought to be due to metastases (Fig.  4) . He died as a consequence of intractable bronchospasm and hypoxia with terminal bronchopneumonia. Autopsy was refused.
We believe this to be a case in which the secretion of both catecholamines and the vaso-and broncho-constrictive peptides contributed to the C.C. (No. 11, Table 1 ) was a 68-year-old white female, who in 1976 developed watery diarrhea and hypokalemia which persisted despite fasting. One year later she had a pathologic fracture of the right pubic ramus. A bone scan revealed metastases in the ribs, sternum, and pelvis. Angiography revealed a 10 x 9 x 7 cm hypervascular mass in the right adrenal region. Preoperative blood samples demonstrated high levels of VIP and a transtumor gradient was shown at surgery when the tumor and the right kidney were removed. The tumor had all the histologic features of a pheochromocytoma. After surgery the diarrhea and hypokalemia resolved and the VIP level returned to normal, although catecholamine levels remained elevated (Table 2 ). In 1981, a 5 x 5 cm para-aortic mass was resected which was histologically a mixed pheochromocytoma-ganglioneuroma. Prior to referral to the University of Michigan in 1982 she was noted to have a 2-cm para-aortic mass by ultrasound and CT and bone scan showed metastases to the occiput (Fig. 5) . ~31I-MIBG scintigraphy showed abnormal foci of uptake in the occiput, superior mediastinum, upper abdomen, periaortic region, and lower abdomen in the region of the aortic bifurcation. Plasma and urinary catecholamines were significantly elevated ( Table 2) . This is an example in which a pheochromocytoma caused the Verner-Morrison syndrome, but subsequent recurrences did not elaborate VIP. This heterogeneity of primary and secondary endocrine tumors is well recognized. 
Discussion
The majority of the highly diverse clinical manifestations of the pheochromocytoma syndrome can be ascribed to hypercatecholaminemia. This is certainly true of hypertension, tachycardia palpitations, sweating, tremor, and headache. Other factors may contribute to the presence of other symptoms, for instance, hypotension (which may be due to epinephrine and perhaps dopamine as well as other postulated neurohumors), glucose intolerance and diabetes, flushing, diarrhea, and constipation. Certainly, the unusual manifestations of diarrhea and bronchospasm demonstrated by the 2 example cases are hard to ascribe to catecholamines alone. Thus, the role of brain-gut neurohumoral peptides acting either alone or in combination with catecholamines and/or other biogenic amines (e.g., serotonin) need to be considered.
The severity of symptoms (including hypertension) are only poorly related to the actual levels of catecholamines. In examining brain-gut peptides that might be hypersecreted in pheochromocytoma and that might give rise to symptomology, the following candidates were considered: 1, Vasoactive intestinal peptide (VIP) is found in the neurons of the intrinsic nervous system of the gut and the adrenal medulla [25, 26] . It has been reported to be present in pheochromocytomas [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , an observation we have confirmed. Hypersecretion of VIP may contribute to diarrhea (sometimes reaching full-blown Verner-Morrison syndrome [37] ), hypotension, and flushing in certain cases of pheochromocytoma [28-31, 34, 35] as in 1 of our patients. In other instances, moderate elevations may be asymptomatic as was the case in 2 of 3 patients with raised VIP levels.
2. Somatostatin (SS) is a neuropeptide with remarkably wide distribution [38] . A clinical syndrome comprising diabetes, diarrhea or steatorrhea, achlorhydria, and biliary disease has been reported in association with somatostatinomas [39] [40] [41] [42] . Its presence has been observed in pheochromocytomas [43] , and was the most common abnormality in our series. Hypersecretion of the neurohumoral peptide may contribute to the glucose intolerance, constipation and/or diarrhea, disordered gut motility, and malabsorption of fats due to suppression of pancreatic exocrine function.
3. Motilin is a peptide hormone found to be present in the enterochromaffin cell of the distal small gut [42] [43] [44] [45] . Its major physiologic function is to promote emptying of the gut in the interdigestive period by stimulating the interdigestive myoelectric complex. Hypersecretion along with serotonin is frequent in carcinoid tumors, [21, [42] [43] [44] [45] another lesion derived from the APUD system. The demonstration of elevated levels of motilin in pheochromocytoma patients is apparently a new observation. Excessively raised levels of motilin may be associated with diarrhea but elevations have been observed as a secondary (compensatory?) phenomenon associated with autonomic neuropathy and paralysis of the stomach and small gut [46] . Thus, extraction of tumors and demonstration of synthesis and secretion of the peptide is needed to implicate fully the pheochromocytoma per se in the production of this peptide.
4. Substance P is a neuropeptide first isolated from the spinal cord by von Euler in 1931 [47] and has since shown to be widely distributed in the central nervous system, including the substantia nigra, and brain stem, as well as the dorsal root ganglia and widely throughout the gut. In the gut the peptide is found in both the enterochromaffin cells and neurones of the myenteric plexus [48] . The peptide is also found in autonomic ganglia and may subserve a function in the sympathetic nervous system [49] . It has been found to increase the catechol synthesizing activity of the enzyme tyrosine-hydroxylase and to initiate the slow excitatory postsynaptic potential [50] . The peptide is a potent vasodilator [51] and may contribute to the flushing and hypotension that occur in pheochromocytoma. It is also a potent vasoconstrictor of bronchial and gut smooth muscle [51] and may cause bronchospasm and diarrhea [52] . Reports have implicated elevated levels of substance P to be associated with episodic wheezing, diarrhea, and flushing in cases of carcinoid syndrome [21, 53, 54] and medullary carcinoma of the thyroid [55] . The symptom complex in our first example case may have been a result of excess production of substance P.
5. Chromogranin and neuron-specific enolase are markers for tumors derived from the APUD system [23, 24, 56] . These features can be detected in tissue by immunohistochemistry as was done in a subgroup of patients in this series or may be present in abnormal concentrations in plasma of patients harboring malignant metastatic tumors. There appears to be no obvious clinical pathophysiological correlation with the presence of high circulating levels of these substances.
There are other peptide neurohormones that may occur in pheochromocytoma but were not examined in this study. These substances are numerous but 2 require specific mention. Since their initial localization in the central nervous system, endogenous opiate peptides have been shown to be widely present in the gut and in the sympathoadrenomedullary system [57] . Peptides of the proopiomelanocortin family appear to be secreted in various concentrations and the clinical syndrome of ectopic adrenocorticotropic hormone (ACTH) with Cushing's syndrome has been observed in pheochromocytoma as well [58] . Unfortunately, we did not measure levels of opiates in tumor or in peripheral plasma. The compound met-enkephalin is especially prominent in pheochromocytomas and may contribute to the constipation which may be severe in this disease [5%65] .
Neuropeptide Y has wide central nervous system distribution and also occurs in the heart, especially in the region of the atrioventricular node and may affect cardiac rate and rhythm [62] [63] [64] [65] [66] [67] . In addition, the compound has profound vasoconstrictor properties and occurs in pheochromocytoma in which it may contribute to the vasoconstriction [68, 69] .
Other factors noted to occur with pheochromocytoma include calcitonin, neurotensin [70] , gastrin [71] , and a hypercalcemic factor [72] , but their role in the clinical symptomatology has not been elucidated.
The peptide neurohormones described above may interact with each other and/or biogenic [73] . These are outlined in Table 3 . A further consideration is that the hypercatecholaminemia may through pharmacological and physiological effects influence the concentrations of circulating neurohumoral brain-gut peptides. This seems to be true for hypergastrinemia, which has been observed in patients with pheochromocytomas [71] . Absolute certainty as to the tumoral production of these peptides would require: demonstration of elevated concentrations in the peripheral circulation; concentration of a transtumoral gradient in the arterial and venous levels of the peptide; elevated concentrations of the peptide within the tumor (which may not occur if storage capacity is limited), and an increase of gene product transcription in the tumor (e.g., messenger RNA). It is only very seldom possible to achieve this level of rigor.
Examination of the data presented in this article and in the literature leads inexorably to the conclusion that pheochromocytomas do secrete brain-gut neurohumoral peptides and that these may contribute to the diverse spectrum of clinical manifestations that can accompany this tumor.
R6sum6
Les ph6ochromocytomes sont g6n6ralement d6cel6spar les effets dfis ~ la surproduction de cat6cholamines, mais certains troubles ne peuvent ~tre attribu6s ~t ce ph6nom6ne et rel6vent peut ~tre de l'action de peptides vasoactifs. Les auteurs se sont donc attach6s ~t doser dans le sang le VIP, la substance P, la somatostatine (SS), et la motiline. Ces dosages furent pratiqu6s 50 fois chez 37 malades porteurs de ph6ochromocytomes: 21 malins, I0 b6nins et 6 ectopiques (5 pm:acardiaque et 1 p6ri-r6nal). Les taux des hormones furent consid6r6s comme 61ev6s lorsque leur niveau fut sup6rieur g plus de 3 fois le taux de 52 sujets sains. Sur les 37 malades 20 (54%) prdsentaient Jan exc6s d'une ou de plusieurs hormones digestives. L'anomalie constatde la plus fr6quente fut l'616va-tion de la SS (9 fois sur 37 soit 24%). Ajoutde gt ce fait fur l'616vation de la VIP chez 3 sujets (8%), de la motiline chez 5 (13.5%) et de la substance P chez 3 (8%). Les phdochromocytomes b6nins surr6naliens pr6sentaient g la lois une 616vation du taux de la SS et de la substance P. Les phdochromocytomes ectopiques en revanche pr6sentaient seulement une 616vation de la SS. Les phdochromocytomes malins pouvaient sdcr6ter les 4 peptides ou plus d'un chez le mdme malade. En conclusion les phdochromocytomes peuvent secrdter de multiples peptides vasoactifs et plus particuli6rement lorsqu'ils sont malins. La SS est la substance qui est la plus souvent secr6tde et elle est trouvde dans les tumeurs bdnignes surrdnaliennes ou ectopiques. Si plus d'une de ces substances est produite en exc~s les risques de malignit6 de la tumeur sont significativement plus importants.
Resumen
Los feocromocitomas generalmente son diagnosticados por los efectos del exceso de producci6n de catecolaminas pero hay caracter~sticas clinicas que no pueden ser atribuidas al exceso de catecolaminas y que pueden set mils bien manifestaci6n de p6ptidos vasoactivos. Hemos establecido los niveles sanguineos del pdptido intestinal vasoactivo (VIP), de la sustancia P, de la somatostatina (SS), y de la motilina en 50 determinaciones en 37 pacientes con feocromocitomas; 21 malignos, 10 benignos intra-adrenales, y 6 ect6picos (5 paracardiales y 1 perirrenal).
Se consider6 que los niveles hormonales estaban elevados cuando el nivel era de mils de 3 de desviaci6n estandar sobre el valor promedio en 52 individuos normales. De 37 pacientes, 20 (54%) presentaron un valor anormal en 1 o mils determinaciones del nivel de hormonas intestinales. La anormalidad mils comtin fue la elevaci6n de la SS en 9/37 (24%). Ademis de esto, sinembargo, otros 3 (8%) presentaban elevaci6n de VIP, 5 (13.5%) elevaci6n de sustancia P. Los adenomas suprarrenales benignos exhibieron niveles elevados de SS y de sustancia P. Los feocromocitomas ect6picos demostraron producci6n s61o de SS ademis de catecolaminas, pero los feocromocitomas malignos demostraron ser capaces de secretar todos los 4 pdptidos, y mils de 1 en el mismo paciente. Hemos llegado a la conclusi6n de que los feocromocitomas pueden secretar mfiltiples 15eptidos vasoactivos y que 6sto tiende a ocurrir cuando son malignos. La SS es el pdptido m~is frecuentemente secretado y se lo encuentra en los tumores suprarrenales benigno y ect6pico (paracardiacos). Si se encuentran niveles elevados de mils de 1 pdptido, la posibilidad de malignidad aparece significativamente aumentada.
